Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Triheptanoin

(Dojolvi®)

Dojolvi®

Drug updated on 4/26/2024

Dosage FormLiquid (oral: 100% w/w of triheptanoin)
Drug ClassMedium-chain triglycerides
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Product Monograph / Prescribing Information

Document TitleYearSource
Dojolvi (triheptanoin) Prescribing Information.2021Ultragenyx Pharmaceutical Inc., Novato, CA

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.
Data not availableSubjects
F: null%
M: null%
2023Journal of Inherited Metabolic Disease
No effect of triheptanoin in patients with phosphofructokinase deficiency.
Data not availableSubjects
F: null%
M: null%
2022Neuromuscular Disorders
A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome.
Data not availableSubjects
F: null%
M: null%
2022Epilepsia
Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
Data not availableSubjects
F: null%
M: null%
2021Journal of Inherited Metabolic Disease
Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study.
Data not availableSubjects
F: null%
M: null%
2021Clinical Nutrition ESPEN

Document Title

Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.

Sex Distribution:

No Data

Year:

2023

Source:Journal of Inherited Metabolic Disease

Document Title

No effect of triheptanoin in patients with phosphofructokinase deficiency.

Sex Distribution:

No Data

Year:

2022

Source:Neuromuscular Disorders

Document Title

A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome.

Sex Distribution:

No Data

Year:

2022

Source:Epilepsia

Document Title

Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.

Sex Distribution:

No Data

Year:

2021

Source:Journal of Inherited Metabolic Disease

Document Title

Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study.

Sex Distribution:

No Data

Year:

2021

Source:Clinical Nutrition ESPEN

Clinical Practice Guidelines

Document TitleYearSource
Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: a clinical practice resource.2023Molecular Genetics and Metabolism
Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): an evidence- and consensus-based approach.2020Molecular Genetics and Metabolism